Linking to Clinical Trials (OB + AACT)
How to join FDA exclusivity data to ClinicalTrials.gov records via RxDataLab's company identity layer. Unlocks pipeline-vs-LOE analysis, reformulation signals, and clinical-stage competitive intelligence.
The Orange Book dataset tracks what is currently protected. ClinicalTrials.gov tracks what companies are developing next. By joining them, we can investigate questions that drive pharmaceutical investment and competitive analysis: which companies are building replacement pipelines for drugs about to go generic? Which late-stage programs represent genuine follow-on innovation versus reformulation defense? Which drugs have both active Paragraph IV challenges and ongoing trials? And many more.
This dataset is coming soon. To be notified when it is available, contact [email protected]